Last $1.07 USD
Change Today +0.3415 / 46.88%
Volume 11.6M
ONCY On Other Exchanges
Symbol
Exchange
Toronto
NASDAQ CM
Frankfurt
As of 4:30 PM 03/2/15 All times are local (Market data is delayed by at least 15 minutes).

oncolytics biotech inc (ONCY) Snapshot

Open
$0.87
Previous Close
$0.73
Day High
$1.10
Day Low
$0.80
52 Week High
03/21/14 - $2.07
52 Week Low
10/10/14 - $0.40
Market Cap
100.1M
Average Volume 10 Days
3.0M
EPS TTM
--
Shares Outstanding
93.5M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for ONCOLYTICS BIOTECH INC (ONCY)

oncolytics biotech inc (ONCY) Related Bloomberg News

View More Bloomberg News

oncolytics biotech inc (ONCY) Related Businessweek News

No Related Businessweek News Found

oncolytics biotech inc (ONCY) Details

Oncolytics Biotech Inc., a development stage biopharmaceutical company, focuses on the discovery and development of pharmaceutical products for the treatment of cancers. The company develops REOLYSIN, a therapeutic reovirus that is in various clinical trials for use as human cancer therapeutic. Its cancer product is a potential therapeutic for tumours possessing an activated Ras pathway. The company was founded in 1998 and is headquartered in Calgary, Canada.

oncolytics biotech inc (ONCY) Top Compensated Officers

Executive Chairman, Chief Executive Officer a...
Total Annual Compensation: C$530.0K
Chief Financial Officer, Principal Accounting...
Total Annual Compensation: C$280.0K
Chief Operating Officer and Director
Total Annual Compensation: C$365.0K
Chief Safety Officer and Senior Vice Presiden...
Total Annual Compensation: C$331.9K
Chief Medical Officer and Senior Vice Preside...
Total Annual Compensation: C$149.8K
Compensation as of Fiscal Year 2013.

oncolytics biotech inc (ONCY) Key Developments

Oncolytics Biotech Inc. Announces Completion of Enrollment in Randomized Phase II Colorectal Cancer Study

Oncolytics Biotech Inc. announced that enrollment has been completed in a randomized Phase II study of REOLYSIN® in patients with advanced or metastatic colorectal cancer (IND 210). The trial is being sponsored and conducted by the NCIC Clinical Trials Group (NCIC CTG) at Queen's University in Kingston, Ontario. This study is an open-label, randomized, non-blinded, phase II clinical study of REOLYSIN® as first-line palliative treatment for patients with advanced or metastatic colorectal cancer. A total of 103 patients were enrolled after completion of a six-patient safety run in. Patients were randomized to receive either FOLFOX-6 and bevacizumab alone (control arm) or FOLFOX-6 and bevacizumab plus REOLYSIN ® (test arm). Patients in both arms received standard doses of FOLFOX-6 and bevacizumab on a bi-weekly basis. Patients in the test arm also received intravenous REOLYSIN® at a dose of 3x10 10 TCID 50 on days one through five of the first, second, fourth, sixth and eighth 14-day cycles, and alternate cycles thereafter.

Oncolytics Biotech Inc. Announces Filing for Orphan Drug Designation with the U.S. FDA for High Grade Gliomas in Pediatric Patients

Oncolytics Biotech Inc. announced that it has submitted an application for Orphan Drug Designation to the U.S. Food and Drug Administration for REOLYSIN® for the treatment of high grade gliomas (HGG) in pediatric patients. Oncolytics has conducted three previous clinical studies in brain cancers including gliomas, and has found that REOLYSIN® can infect a variety of brain tumors when delivered intravenously. The FDA grants Orphan Drug Designation status to products that treat rare diseases, providing incentives to sponsors developing drugs or biologics. The FDA defines rare diseases as those affecting fewer than 200,000 people in the United States at any given time. Orphan Drug Designation provides the sponsor certain benefits and incentives, including a period of marketing exclusivity if regulatory approval is ultimately received for the designated indication, potential tax credits for certain activities, eligibility for orphan drug grants, and the waiver of certain administrative fees. The receipt of Orphan Drug Designation status does not change the regulatory requirements or process for obtaining marketing approval.

Oncolytics Biotech Inc. Announces Filing for Orphan Drug Designation with the U.S. FDA for Pancreatic and Ovarian Cancers

Oncolytics Biotech Inc. announced that it has submitted applications for Orphan Drug Designation to the U.S. Food and Drug Administration for REOLYSIN® for the treatment of pancreatic and ovarian cancers. The FDA grants Orphan Drug Designation status to products that treat rare diseases, providing incentives to sponsors developing drugs or biologics. The FDA defines rare diseases as those affecting fewer than 200,000 people in the United States at any given time. Orphan Drug Designation provides the sponsor certain benefits and incentives, including a period of marketing exclusivity if regulatory approval is ultimately received for the designated indication, potential tax credits for certain activities, eligibility for orphan drug grants, and the waiver of certain administrative fees.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
ONCY:US $1.07 USD +0.3415

ONCY Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for ONCY.
View Industry Companies
 

Industry Analysis

ONCY

Industry Average

Valuation ONCY Industry Range
Price/Earnings NM Not Meaningful
Price/Sales -- Not Meaningful
Price/Book 4.9x
Price/Cash Flow NM Not Meaningful
TEV/Sales -- Not Meaningful
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ONCOLYTICS BIOTECH INC, please visit www.oncolyticsbiotech.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.